Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 6/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627570 | 1.00 | NR1I2 (0.59) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL2836659 | 1.00 | NR1I2 (0.59) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL116152 | 0.91 | NR1I2 (0.71) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL116153 | 0.91 | NR1I2 (0.71) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL2834686 | 0.89 | NR1I2 (0.68) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL2832876 | 0.89 | NR1I2 (0.68) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL2836836 | 0.89 | NR1I2 (0.68) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL2836407 | 0.89 | NR1I2 (0.68) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL2833805 | 0.89 | NR1I2 (0.68) | NR1I2LMNAPGRSQLEALOX15 | |
| SCHEMBL5200405 | 0.85 | NR1I2 (0.59) | NR1I2LMNAPGRSQLEALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013144595-A1 | PERIDININ-CHLOROPHYLL BINDING PROTEINS | PROTEIN TECHNOLOGIES LIMITED (GB) | 2013-10-03 | — | — | WO | claimed |
| US-20260144834-A1 | ANTIMICROBIAL FEED ADDITIVE | Axitan Ltd. (GB) | 2026-05-28 | — | — | US | disclosed |
| US-20260123660-A1 | Particles Containing a Lipid Matrix Core and Active Ingredient | LONZA SALES AG (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4054348-B1 | PARTICLES CONTAINING A LIPID MATRIX CORE AND ACTIVE INGREDIENT | LONZA SALES AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12471609-B2 | Reducing the risk of viral infection due to viral contaminated feed | NOVUS INTERNATIONAL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12465075-B2 | Particles containing a lipid matrix core and active ingredient | LONZA SALES AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4642253-A1 | USE OF MICROALGAE AND MICROALGAE DERIVED COMPONENTS IN CULTIVATED FOOD PRODUCTION | Weforesea Ltd. (IL) | 2025-11-05 | — | — | EP | disclosed |
| US-20250281440-A1 | METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE | NUTRIQUEST, LLC | 2025-09-11 | — | — | US | disclosed |
| US-12349704-B2 | High quality cultured meat, compositions and methods for producing same | ALEPH FARMS LTD. (IL) | 2025-07-08 | — | — | US | disclosed |
| US-12310386-B2 | Reducing the risk of viral infection due to viral contaminated feed | NOVUS INTERNATIONAL, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-03 | — | — | US | disclosed |
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMA, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| CN-1325267-A | Fused-benzene derivatives useful as herbicides | ISHIHARA SANGYO KAISHA (JP) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037995-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CPT1A, TXNRD2, PC | NR1I2 327/4885LMNA 1111/4885PGR 3696/4885 |
| US-20260144834-A1 | ANTIMICROBIAL FEED ADDITIVE | ELOVL6, CROCC, ELOC | NR1I2 1086/4885LMNA 2049/4885PGR 4682/4885 |
| US-20250281440-A1 | METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE | PIGS, GLO1, IGFBP6 | NR1I2 4701/4885LMNA 1769/4885PGR 2217/4885 |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | NR1I2 1749/4885LMNA 29/4885PGR 2684/4885 |
| US-20050009930-A1 | Carotenoid analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | NR1I2 1843/4885LMNA 34/4885PGR 2818/4885 |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | TTPA, PROC, RBP4 | NR1I2 1487/4885LMNA 3024/4885PGR 2454/4885 |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | RBP1, PROC, RBP4 | NR1I2 1858/4885LMNA 2708/4885PGR 2689/4885 |
| US-20050026874-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | NR1I2 124/4885LMNA 716/4885PGR 2761/4885 |
| US-20260123660-A1 | Particles Containing a Lipid Matrix Core and Active Ingredient | AUP1, MGLL, MBOAT4 | NR1I2 2608/4885LMNA 1876/4885PGR 859/4885 |
| US-20050049248-A1 | Carotenoid ether analogs or derivatives for controlling C-reactive protein levels | PROC, TTPA, CYC1 | NR1I2 1344/4885LMNA 2351/4885PGR 1989/4885 |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | NFE2L2, GPX4, CYP11B2 | NR1I2 645/4885LMNA 685/4885PGR 2215/4885 |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | NR1I2 164/4885LMNA 870/4885PGR 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.